Measurable residual disease (MRD) can be determined using a variety of techniques. However, the majority of trials perform bone marrow MRD evaluation, while few are determining the effectiveness of PET-CT and MRI. Here, Elena Zamagni, MD, PhD, from the University of Bologna, Bologna, Italy, explains some of the complications regarding interpreting patient MRD and how incorporating these imaging techniques could help reduce this ambiguity. This interview took place at the 1st European Myeloma Network (EMN) Meeting, held in Turin, Italy.
EMN18_Zamagni_VJHO_02
